search
Back to results

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Primary Purpose

Cancer, Neoplasm

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
SAR444881
Pembrolizumab
Cetuximab
Carboplatin
Pemetrexed
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy
  • Histologic confirmation of malignancy
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1
  • Participants must have adequate organ function as defined by lab tests
  • Part 1: Following tumor types: Breast cancer, cervical cancer, colorectal cancer, adenocarcinoma or squamous cell carcinoma of the esophagus, gastric or gastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, hepatobiliary cancers (hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma), non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the skin, or urothelial carcinoma
  • Part 2: Following tumor types: Squamous cell carcinoma of the head and neck, Gastric or gastroesophageal junction adenocarcinoma, Non-small cell lung cancer

Exclusion Criteria:

  • Active, known or suspected autoimmune disease
  • Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
  • Brain or leptomeningeal metastases
  • Known history of positive test for HIV
  • Non-HCC patients: acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV); HCC patients: untreated active HBV or dual infection with HBV/HCV
  • Participants after solid organ or allogeneic hematopoietic stem cell transplant
  • History of life-threatening toxicity related to prior immune therapy
  • History of life-threatening toxicity related to prior cetuximab or other anti-EGFR antibodies (for Sub-Part 1C)
  • Unstable or deteriorating cardiovascular disease within the previous 6 months
  • Any major surgery within 4 weeks of study drug administration
  • Prior/Concomitant Therapy:
  • Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsed from last dose
  • Use of other investigational drugs within 28 days
  • Prior treatment with macrophage or natural killer (NK) cells activating therapies
  • Administration of a live attenuated vaccine within 28 days

Sites / Locations

  • Mayo ClinicRecruiting
  • City of Hope Comprehensive Cancer CenterRecruiting
  • University of Colorado Cancer CenterRecruiting
  • Yale Cancer CenterRecruiting
  • Mayo ClinicRecruiting
  • Rambam Health Care CampusRecruiting
  • Hadassah University Medical CenterRecruiting
  • Rabin Medical CenterRecruiting
  • Sheba Medical CenterRecruiting
  • Tel Aviv Sourasky Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

SAR444881 Dose Escalation (Sub-Part 1A)

SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)

SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)

SAR444881 Dose Optimization (Sub-Part 2A)

SAR444881 Dose Expansion (Sub-Part 2B)

Arm Description

Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W).

Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W).

Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W).

SAR444881 Dose Optimization in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), NSCLC, gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.

The indication for this monotherapy cohort will be either relapsed or refractory NSCLC, head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, or GC/GEJ. Enrollment will be opened based on emerging data from the dose-escalation phase and combination optimization data.

Outcomes

Primary Outcome Measures

Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)
Incidence of TEAEs meeting protocol defined DLT criteria
Part 1: Incidence of treatment-emergent adverse events and serious adverse events
Part 2: Objective Response Rate (ORR) per RECIST v1.1
Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1

Secondary Outcome Measures

Part 1: Objective Response Rate (ORR) per RECIST v1.1
Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1
Part 1: Maximum observed plasma concentration [Cmax]
Part 1: Serum concentration at the end of the dosing interval (Ctrough)
Part 1: time of maximum observed serum concentration (Tmax)
Part 1: Terminal elimination half-life [T1/2]
Part 1: Area under the plasma concentration-time curve [AUC]
Part 1: Incidence of anti-drug antibodies (ADA)
Part 2: Progression Free Survival
Time from the date of first dose of study drug to the date of first documented disease progression or death due to any cause, whichever occurs first
Part 2: Duration of Response
Duration between first documentation of CR or PR to first documentation of disease progression or death due to any cause, whichever occurs first
Part 2: Incidence of treatment-emergent adverse events and Serious Adverse Events
Part 2: Cmax
Part 2: Ctrough
Part 2: Tmax
Part 2: T1/2
Part 2: AUC
Part 2: Incidence of ADA

Full Information

First Posted
January 15, 2021
Last Updated
September 18, 2023
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT04717375
Brief Title
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Official Title
A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 11, 2021 (Actual)
Primary Completion Date
May 14, 2027 (Anticipated)
Study Completion Date
May 14, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 is comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of SAR444881 per indication are administered in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed (Sub-Part 2A); and a dose expansion part where SAR444881 is administered alone (Sub-Part 2B). In Sub-Part 2A, a two-stage design will be implemented to conduct dose optimization for each indication with combination therapy- Stage 1 (Preliminary Assessment) and Stage 2 (Randomization). Study is non-randomized except Stage 2 of Sub-Part 2A which will use randomization.
Detailed Description
Estimated Study Duration: Dose Escalation (Part 1): Approximately 34 months Dose Optimization/Expansion (Part 2): Approximately 28 months

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Neoplasm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
456 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SAR444881 Dose Escalation (Sub-Part 1A)
Arm Type
Experimental
Arm Description
Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W).
Arm Title
SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)
Arm Type
Experimental
Arm Description
Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W).
Arm Title
SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)
Arm Type
Experimental
Arm Description
Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W).
Arm Title
SAR444881 Dose Optimization (Sub-Part 2A)
Arm Type
Experimental
Arm Description
SAR444881 Dose Optimization in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), NSCLC, gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
Arm Title
SAR444881 Dose Expansion (Sub-Part 2B)
Arm Type
Experimental
Arm Description
The indication for this monotherapy cohort will be either relapsed or refractory NSCLC, head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, or GC/GEJ. Enrollment will be opened based on emerging data from the dose-escalation phase and combination optimization data.
Intervention Type
Drug
Intervention Name(s)
SAR444881
Other Intervention Name(s)
BND-22
Intervention Description
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Intervention Description
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Intervention Type
Drug
Intervention Name(s)
Cetuximab
Intervention Description
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
Intervention Type
Drug
Intervention Name(s)
Pemetrexed
Intervention Description
Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
Primary Outcome Measure Information:
Title
Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)
Description
Incidence of TEAEs meeting protocol defined DLT criteria
Time Frame
Cycle 1 (28 days)
Title
Part 1: Incidence of treatment-emergent adverse events and serious adverse events
Time Frame
Through study completion, an average of 5 months
Title
Part 2: Objective Response Rate (ORR) per RECIST v1.1
Description
Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1
Time Frame
Through study completion, an average of 3 months
Secondary Outcome Measure Information:
Title
Part 1: Objective Response Rate (ORR) per RECIST v1.1
Description
Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1
Time Frame
Through study completion, an average of 3 months
Title
Part 1: Maximum observed plasma concentration [Cmax]
Time Frame
Through study completion, an average of 2 months
Title
Part 1: Serum concentration at the end of the dosing interval (Ctrough)
Time Frame
Through study completion, an average of 2 months
Title
Part 1: time of maximum observed serum concentration (Tmax)
Time Frame
Through study completion, an average of 2 months
Title
Part 1: Terminal elimination half-life [T1/2]
Time Frame
Through study completion, an average of 2 months
Title
Part 1: Area under the plasma concentration-time curve [AUC]
Time Frame
Through study completion, an average of 2 months
Title
Part 1: Incidence of anti-drug antibodies (ADA)
Time Frame
Through study completion, an average of 5 months
Title
Part 2: Progression Free Survival
Description
Time from the date of first dose of study drug to the date of first documented disease progression or death due to any cause, whichever occurs first
Time Frame
Through study completion, an average of 3 months
Title
Part 2: Duration of Response
Description
Duration between first documentation of CR or PR to first documentation of disease progression or death due to any cause, whichever occurs first
Time Frame
Through study completion, an average of 6 months
Title
Part 2: Incidence of treatment-emergent adverse events and Serious Adverse Events
Time Frame
Through study completion, an average of 6 months
Title
Part 2: Cmax
Time Frame
Through study completion, an average of 3 months
Title
Part 2: Ctrough
Time Frame
Through study completion, an average of 3 months
Title
Part 2: Tmax
Time Frame
Through study completion, an average of 3 months
Title
Part 2: T1/2
Time Frame
Through study completion, an average of 3 months
Title
Part 2: AUC
Time Frame
Through study completion, an average of 3 months
Title
Part 2: Incidence of ADA
Time Frame
Through study completion, an average of 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy Histologic confirmation of malignancy Measurable disease per RECIST v1.1 Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1 Participants must have adequate organ function as defined by laboratory tests Part 1: Following tumor types: Breast cancer, cervical cancer, colorectal cancer, adenocarcinoma or squamous cell carcinoma of the esophagus, gastric or gastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, hepatobiliary cancers (hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma), non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the skin, pancreatic adenocarcinoma, ovarian cancer or urothelial carcinoma Part 2: Following tumor types: Squamous cell carcinoma of the head and neck, Gastric or gastroesophageal junction adenocarcinoma, non-squamous non-small cell lung cancer, non-small cell lung cancer, colorectal carcinoma (CRC) any RAS, and/or Cholangiocarcinoma Exclusion Criteria: Active, known or suspected autoimmune disease Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications Brain or leptomeningeal metastases Known history of positive test for HIV Non-HCC patients: acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV); HCC patients: untreated active HBV or dual infection with HBV/HCV Participants after solid organ or allogeneic hematopoietic stem cell transplant History of life-threatening toxicity related to prior immune therapy History of life-threatening toxicity related to prior cetuximab or other anti-EGFR antibodies (for Sub-Part 1C) Unstable or deteriorating cardiovascular disease within the previous 6 months Any major surgery within 4 weeks of study drug administration Prior/Concomitant Therapy: Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsed from last dose Use of other investigational drugs within 28 days Prior treatment with macrophage or natural killer (NK) cells activating therapies Administration of a live attenuated vaccine within 28 days The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Trial Transparency email recommended (Toll free for US & Canada)
Phone
800-633-1610
Ext
option 6
Email
Contact-US@sanofi.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mitesh Borad, MD
Phone
480-342-4800
Facility Name
City of Hope Comprehensive Cancer Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marwan Fakih, MD
Phone
626-256-4673
Ext
83087
Email
mfakih@coh.org
Facility Name
University of Colorado Cancer Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Lieu, MD
Phone
720-848-3532
Email
CHRISTOPHER.LIEU@CUANSCHUTZ.EDU
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Palma
Phone
203-200-2486
Email
Ingrid.palma@yale.edu
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhaohui Jin, MD
Phone
507-284-2511
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liat Rapaport
Phone
972-4-777-6731
Email
L_Rapaport@rambam.health.gov.il
Facility Name
Hadassah University Medical Center
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cecilia Lellouche
Phone
972-2-6779129
Email
CECILIAL@hadassah.org.il
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gal Medalia
Phone
972-3-937-8023
Email
Galmed@clalit.org.il
Facility Name
Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilanit Redinsky
Phone
972-3-530-4498
Email
Ilanit.Redinsky@sheba.health.gov.il
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Limor Ben Zvi
Phone
972-3-697-3193
Email
limorb@tlvmc.gov.il

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36096532
Citation
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T. BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859.
Results Reference
derived

Learn more about this trial

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

We'll reach out to this number within 24 hrs